Table 3.
Pathways over-represented in the first-order 812 gene network
| Pathway | Total | Expected | Hits | p value | FDR |
|---|---|---|---|---|---|
| Pathways in cancer | 310 | 80.9 | 197 | 6.53E−47 | 1.42E−44 |
| ErbB signaling pathway | 87 | 22.7 | 70 | 1.35E−26 | 1.47E−24 |
| Chronic myeloid leukemia | 73 | 19.1 | 62 | 3.38E−26 | 2.45E−24 |
| HTLV-I infection | 199 | 52 | 121 | 5.30E−26 | 2.78E−24 |
| WNT signaling pathway | 144 | 37.6 | 97 | 6.41E−26 | 2.78E−24 |
| Focal adhesion | 200 | 52.2 | 117 | 4.23E−23 | 1.53E−21 |
| Pancreatic cancer | 69 | 18 | 56 | 8.10E−22 | 2.51E−20 |
| Neurotrophin signaling pathway | 123 | 32.1 | 82 | 1.39E−21 | 3.78E−20 |
| Prostate cancer | 87 | 22.7 | 64 | 1.27E−20 | 3.07E−19 |
| Colorectal cancer | 49 | 12.8 | 43 | 1.21E−19 | 2.63E−18 |
| Osteoclast differentiation | 119 | 31.1 | 77 | 3.84E−19 | 7.58E−18 |
| Acute myeloid leukemia | 57 | 14.9 | 47 | 4.98E−19 | 9.01E−18 |
| Hepatitis C | 100 | 26.1 | 68 | 8.76E−19 | 1.46E−17 |
| T cell receptor signaling pathway | 98 | 25.6 | 67 | 1.02E−18 | 1.58E−17 |
| Melanogenesis | 101 | 26.4 | 68 | 2.02E−18 | 2.92E−17 |
| Regulation of actin cytoskeleton | 182 | 47.5 | 102 | 2.39E−18 | 3.24E−17 |
| Chagas disease (American trypanosomiasis) | 89 | 23.2 | 62 | 4.82E−18 | 6.15E−17 |
| MAPK signaling pathway | 265 | 69.2 | 132 | 1.51E−17 | 1.82E−16 |
| B cell receptor signaling pathway | 75 | 19.6 | 54 | 7.04E−17 | 8.04E−16 |
| Gap junction | 89 | 23.2 | 60 | 1.99E−16 | 2.16E−15 |
| Renal cell carcinoma | 60 | 15.7 | 46 | 2.51E−16 | 2.60E−15 |
| Epstein-Barr virus infection | 91 | 23.8 | 60 | 9.93E−16 | 9.79E−15 |
| Cell cycle | 124 | 32.4 | 74 | 1.37E−15 | 1.30E−14 |
| Axon guidance | 118 | 30.8 | 71 | 2.90E−15 | 2.62E−14 |
| Toll-like receptor signaling pathway | 97 | 25.3 | 62 | 3.02E−15 | 2.62E−14 |
| Glioma | 65 | 17 | 47 | 5.85E−15 | 4.88E−14 |
| Herpes simplex infection | 103 | 26.9 | 64 | 7.95E−15 | 6.39E−14 |